Teva Pharmaceutical Industries Ltd (NYSE:TEVA) was downgraded by Vetr from a “strong-buy” rating to a “buy” rating in a research report issued on Thursday. They currently have a $36.17 price target on the stock. Vetr‘s target price points to a potential upside of 17.59% from the stock’s previous close.
TEVA has been the topic of a number of other reports. Maxim Group cut shares of Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating and reduced their price target for the company from $49.00 to $41.00 in a research report on Friday, January 6th. Oppenheimer Holdings Inc. reiterated an “outperform” rating on shares of Teva Pharmaceutical Industries in a research report on Wednesday, December 7th. Royal Bank of Canada set a $42.00 price target on shares of Teva Pharmaceutical Industries and gave the company a “buy” rating in a research report on Monday, January 9th. Guggenheim reiterated a “buy” rating and set a $80.00 price target on shares of Teva Pharmaceutical Industries in a research report on Friday, December 23rd. Finally, Sanford C. Bernstein reiterated an “outperform” rating and set a $42.00 price target on shares of Teva Pharmaceutical Industries in a research report on Friday, February 24th. One research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $45.14.
Teva Pharmaceutical Industries (NYSE:TEVA) traded up 1.252% during mid-day trading on Thursday, reaching $31.145. 4,525,655 shares of the company were exchanged. The stock has a market capitalization of $31.61 billion, a price-to-earnings ratio of 444.929 and a beta of 0.58. Teva Pharmaceutical Industries has a 12-month low of $30.57 and a 12-month high of $57.52. The company’s 50 day moving average price is $32.75 and its 200-day moving average price is $36.56. Teva Pharmaceutical Industries also was the target of some unusual options trading activity on Thursday. Investors acquired 422 put options on the company. This is an increase of 111% compared to the average volume of 200 put options.
Teva Pharmaceutical Industries (NYSE:TEVA) last announced its earnings results on Monday, February 13th. The company reported $1.38 earnings per share for the quarter, beating analysts’ consensus estimates of $1.36 by $0.02. The business had revenue of $6.25 billion for the quarter, compared to the consensus estimate of $6.26 billion. Teva Pharmaceutical Industries had a net margin of 1.50% and a return on equity of 17.46%. Teva Pharmaceutical Industries’s quarterly revenue was up 33.0% on a year-over-year basis. During the same period last year, the firm posted $1.32 earnings per share. On average, equities research analysts forecast that Teva Pharmaceutical Industries will post $4.82 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This article was originally posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this article on another site, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The correct version of this article can be viewed at https://www.chaffeybreeze.com/2017/04/21/teva-pharmaceutical-industries-ltd-teva-downgraded-to-buy-at-vetr-inc-2-updated.html.
Large investors have recently added to or reduced their stakes in the company. Cribstone Capital Management LLC increased its stake in Teva Pharmaceutical Industries by 3.3% in the first quarter. Cribstone Capital Management LLC now owns 3,141 shares of the company’s stock valued at $101,000 after buying an additional 100 shares during the last quarter. JFS Wealth Advisors LLC increased its stake in Teva Pharmaceutical Industries by 139.0% in the third quarter. JFS Wealth Advisors LLC now owns 2,495 shares of the company’s stock worth $115,000 after buying an additional 1,451 shares in the last quarter. BKS Advisors LLC purchased a new stake in Teva Pharmaceutical Industries during the third quarter worth about $115,000. Elite Wealth Management LLC purchased a new stake in Teva Pharmaceutical Industries during the third quarter worth about $166,000. Finally, CKW Financial Group purchased a new stake in Teva Pharmaceutical Industries during the third quarter worth about $168,000. Institutional investors own 55.03% of the company’s stock.
Teva Pharmaceutical Industries Company Profile
Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.
To view Vetr’s full report, visit Vetr’s official website.
Receive News & Ratings for Teva Pharmaceutical Industries Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Ltd and related companies with MarketBeat.com's FREE daily email newsletter.